Tác dụng không mong muốn của hoá xạ trị trên ung thư biểu mô tuyến phổi giai đoạn III bằng phác đồ cisplatin kết hợp với etoposide hoặc pemetrexed

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Mai Lan Nguyễn, Thị Thái Hoà Nguyễn, Thế Cường Trịnh

Ngôn ngữ: vie

Ký hiệu phân loại: 571.45 *Radiobiology

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2022

Mô tả vật lý: 82-85

Bộ sưu tập: Metadata

ID: 500253

Thêm vào giỏ

Tóm tắt
Chủ đề

Concurrent chemoradiotherapy is the primary treatment of inoperable stage III non-small cell lung cancer. For adenocarcinoma, the chemotherapy regimen commonly applied in clinical practice at K Hospital is Etoposide - Cisplatin (EP) or Pemetrexed - Cisplatin (PeC). The objective of the study was to evaluate the side effects of chemotherapy with 2 regimens EP and PeC concurrent with radiotherapy. Subjects and methods: Retrospective study toevaluate side effects of 50 patients treated with Etoposide - Cisplatin (EP) regimen and 31 patients treated with Pemetrexed - Cisplatin (PeC) regimen concurrently with 3D radiation therapy for inoperable stage III adenocarcinoma of lung. Results: The rates of hemoglobinia , neutropenia and thrombocytopenia of EP and PeC regimens were 76%, 84% and 28% and 51.6%, 41.9% and 12.9%, respectively. The rates of hemoglobinia and neutropenia were statistically significantly lower with the PeC regimen than with EP. The rates of pneumonia, esophagitis and dry skin of the two regimens were 22%, 66% and 62% with EP and 16.1%, 48.4% and 45.1% with PeC, respectively., Fatigue rate of 51.6% PeC regimen was significantly lower than that of EP regimen of 84%. Conclusion: The PeC regimen had significantly lower rates of fatigue, hemoglobinia, and neutropenia than the EP regimen.Hoá xạ trị đồng thời là điều trị căn bản của ung thư phổi không tế bào nhỏ giai đoạn III không mổ được. Đối với ung thư biểu mô tuyến, phác đồ hoá trị thường được áp dụng trên thực tế lâm sàng tại Bệnh viện K là Etoposide - Cisplatin (EP) hoặc Pemetrexed - Cisplatin (PeC). Mục tiêu của nghiên cứu là đánh giá tác dụng không mong muốn của hoá xạ trị đồng thời với 2 phác đồ EP và PeC. Đối tượng và phương pháp: Nghiên cứu hồi cứu đánh giá tác dụng không mong muốn của 50 bệnh nhân điều trị phác đồ Etoposide - Cisplatin (EP) và 31 bệnh nhân điều trị phác đồ Pemetrexed - Cisplatin (PeC) đồng thời với tia xạ 3D cho ung thư biểu mô tuyến phổi giai đoạn III không mổ được. Kết quả: Tỷ lệ hạ huyết sắc tố, hạ bạch cầu trung tính và hạ tiểu cầu của phác đồ EP và PeC tương ứng là 76%, 84% và 28% và 51,6%, 41,9% và 12,9%. Tỷ lệ hạ huyết sắc tố và hạ bạch cầu trung tính của phác đồ PeC thấp hơn có ý nghĩa thống kê so với EP. Tỷ lệ viêm phổi, viêm thực quản và khô da của hai phác đồ lần lượt là 22%, 66% và 62% với EP và 16,1%, 48,4% và 45,1% với PeC. Tỷ lệ mệt mỏi của phác đồ PeC 51,6% thấp hơn có ý nghĩa so với phác đồ EP là 84%. Kết luận: Phác đồ PeC có tỷ lệ mệt mỏi, hạ huyết sắc tố, hạ bạch cầu trung tính thấp hơn có ý nghĩa so với phác đồ EP

Tạo bộ sưu tập với mã QR